Janssen Biotech Inc. acquires license from Novo Nordisk for a development program focused on autoimmune diseases

Terms of the agreement have not been disclosed.

PRESS RELEASE

Bagsværd, Denmark, 20 May 2015 - Novo Nordisk A/S has signed an agreement with Janssen Biotech, Inc. (Janssen) under which Janssen will acquire an exclusive global licence to further develop and commercialise a clinical programme focused on therapy within autoimmune diseases. The programme targets modulation of certain immune cells via a cell surface receptor (NKG2D receptor). Terms of the agreement have not been disclosed.

The agreement is subject to final clearance under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR) with the U.S. Department of Justice Antitrust Division and the Federal Trade Commission.